A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants
← catalyst calendarNCT07727538 · readout ≤ 1,473 d
Sponsored by Ionis Pharmaceuticals, Inc. (industry) · IONS — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
12estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-31 | actual | When the study began enrolling |
| Primary completion | Aug 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Familial Chylomicronemia Syndrome
Intervention
- Drug: Olezarsen — also filed as ISIS 678354
Primary outcome
what the primary-completion date above is the date OFPercent Change from Baseline in Fasting Triglycerides (TG)
measured At 6 Months
Permalink · IONS's whole pipeline · Catalyst calendar · Every registered study · What changed